Oppenheimer & Co’s ARK Genomic Revolution ETF ARKG Stock Holding History

Oppenheimer & Co’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$364K	Buy	13,771 +1,345	+11%	+$39.4K	﹤0.01%	1314
2025 Q4	$360K	Buy	+12,426	New	+$373K	0.01%	1208
2025 Q3	–	Sell	-19,816	Closed	-$483K	–	1656
2025 Q2	$483K	Buy	19,816 +1,153	+6%	+$25.3K	0.01%	1158
2025 Q1	$387K	Buy	+18,663	New	+$469K	0.01%	1170
2022 Q3	–	Sell	-7,801	Closed	-$245K	–	1370
2022 Q2	$245K	Sell	7,801 -7,199	-48%	-$252K	0.01%	1180
2022 Q1	$689K	Buy	15,000 +664	+5%	+$31.7K	0.01%	886
2021 Q4	$877K	Sell	14,336 -4,093	-22%	-$283K	0.02%	827
2021 Q3	$1.38M	Sell	18,429 -122	-0.7%	-$10.2K	0.03%	629
2021 Q2	$1.72M	Buy	18,551 +3,645	+24%	+$310K	0.03%	566
2021 Q1	$1.32M	Buy	14,906 +9,901	+198%	+$982K	0.03%	603
2020 Q4	$467K	Buy	5,005 +470	+10%	+$37.4K	0.01%	920
2020 Q3	$289K	Buy	+4,535	New	+$266K	0.01%	997

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Oppenheimer & Co's ARKG Position: Q1 2026 in Review

Oppenheimer & Co increased its ARK Genomic Revolution ETF (ARKG) stake by 11% in Q1 2026, buying an estimated $39.4K and bringing the position to 13,771 shares worth $364K. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

Oppenheimer & Co first reported a position in ARKG in Q3 2020 and has held it in 12 quarters since. The position peaked at $1.72M in Q2 2021. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

Oppenheimer & Co held 13,771 shares of ARK Genomic Revolution ETF worth $364K as of Q1 2026.
Oppenheimer & Co bought 1,345 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $39.4K.
ARK Genomic Revolution ETF made up ﹤0.01% of Oppenheimer & Co's portfolio in Q1 2026, its #1314 holding.
Oppenheimer & Co first reported a position in ARK Genomic Revolution ETF in Q3 2020 and has held it in 12 quarters since.
Oppenheimer & Co's ARK Genomic Revolution ETF position peaked at $1.72M in Q2 2021.
218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Oppenheimer & Co's 13F filing for Q1 2026, filed 24 Apr 2026.